LobbyingHikma Pharmaceuticals USA lobbying by quarter
Hikma Pharmaceuticals USA's latest lobbying report covers Q2 2026, at $60K. The four quarters Q3 2025–Q2 2026 total $150K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Trade (Domestic & Foreign).
Hikma Pharmaceuticals USA
- Latest quarter
- $60K
- Q2 2026 · 1 reports
- Last 12 months
- $150K
- Last 4 quarters
- vs last quarter
- +100.0%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $30K | 1 |
| Q1 2023 | $50K | 1 |
| Q2 2023 | $60K | 1 |
| Q3 2023 | $50K | 1 |
| Q4 2023 | $40K | 1 |
| Q1 2024 | $30K | 1 |
| Q2 2024 | $30K | 1 |
| Q3 2024 | $20K | 1 |
| Q4 2024 | $30K | 1 |
| Q1 2025 | $40K | 1 |
| Q2 2025 | $60K | 1 |
| Q3 2025 | $20K | 1 |
| Q4 2025 | $40K | 1 |
| Q1 2026 | $30K | 1 |
| Q2 2026 | $60K | 1 |
Policy issues the reports name
- Health issues15 reports
- Trade6 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- White House Office7 reports
- Health & Human Services, Dept of (HHS)5 reports
- Commerce, Dept of (DOC)4 reports
- Food & Drug Administration (FDA)4 reports
- Office of Natl Drug Control Policy (NDCP)3 reports
- Drug Enforcement Administration (DEA)2 reports
- Office of Management & Budget (OMB)2 reports
- U.S. Trade Representative (USTR)2 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
- State, Dept of (DOS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Apco Worldwide | $590K | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ALLISON PARKER-LAGOO | Assistant to the Chief of Staff, Sen. Hagan | Q2 2026 |
| DAN SCANDLING | Chief of Staff & Press Secretary, Rep. Bateman | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Apco Worldwide | $60K |
| 04/20for Q1 | Apco Worldwide | $30K |
| 01/15for Q4 2025 | Apco Worldwide | $40K |
| 25/10/17for Q3 2025 | Apco Worldwide | $20K |
| 25/07/15for Q2 2025 | Apco Worldwide | $60K |
| 25/04/17for Q1 2025 | Apco Worldwide | $40K |
| 25/01/13for Q4 2024 | Apco Worldwide | $30K |
| 24/10/16for Q3 2024 | Apco Worldwide | $20K |
| 24/07/18for Q2 2024 | Apco Worldwide | $30K |
| 24/04/15for Q1 2024 | Apco Worldwide | $30K |
| 24/01/16for Q4 2023 | Apco Worldwide | $40K |
| 23/10/18for Q3 2023 | Apco Worldwide | $50K |
| 23/07/20for Q2 2023 | Apco Worldwide | $60K |
| 23/04/18for Q1 2023 | Apco Worldwide | $50K |
| 23/01/13for Q4 2022 | Apco Worldwide | $30K |